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Himanshu J. Patel, MDSEE PAGE 2363B icuspid aortic valve (BAV) syndrome is a het-erogeneous inheritable condition estimatedto occur in 0.5% to 2% of the general popula-
tion (1). Its phenotypic expression ranges from a
“true” bicuspid valve associated with 2 sinuses of
Valsalva to a “functional” bicuspid valve, in which 3
sinuses of Valsalva exist but 2 of the aortic cusps
have varying degrees of fusion. The latter type results
in fusion of a combination of any 2 of the 3 cusps,
with a resulting asymmetric sinus of Valsalva. Associ-
ated lesions also can include coarctation of the aorta
and ventricular septal defects.
BAV syndrome is often associated with an aortop-
athy, which is expressed in 1 of 4 ways: root,
ascending and proximal arch aorta dilation, normal
root with only ascending and arch aorta dilation, and
either root or ascending aorta dilation alone (2). On
the basis of pathological ﬁndings of medial degener-
ation also commonly seen in Marfan syndrome (MFS),
an assumption regarding the virulent nature of BAV
aortopathy led to recommendations for surgery that
resembled those for Marfan syndrome (i.e., aneurysm
diameter threshold of 5.0 cm) (3). Important dif-
ferences do exist, as is evidenced by the dismal
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patients with MFS who do not undergo prophylactic
root replacement, BAV displays a spectrum of clinical
presentation ranging from indolence to acute dissec-
tion. Recognition of these differences led to the newer
guideline recommendations for elective thoracic
aneurysmectomy for BAV syndrome (now 5.5 cm) (5).In this issue of the Journal, Itagaki et al. (6) have
reported a timely study, describing the comparative
late risks for aneurysm and dissection in patients with
BAVs and MFS. The source of the data was the
Statewide Planning and Research Cooperative Sys-
tem, an administrative database on every hospitali-
zation and emergency department visit in New York
State. Using coding diagnoses, they identiﬁed
patients who underwent primary aortic valve replace-
ment with an associated BAV (n ¼ 2,079) or MFS
(n ¼ 73) and compared late aortic outcomes in these
2 groups with a control group of patients (n ¼ 11,053)
treated for rheumatic aortic valve disease. Those
patients with a history of or undergoing concomitant
aortic repair, or a history of other valvular or coronary
artery surgery, were excluded. Other patients with
genetic syndromes or inﬂammatory diseases that
could potentially affect aortic growth were also
excluded.
Their unique ﬁndings are as follows:
1. The control group had a signiﬁcantly (and sur-
prisingly) high rate of operative mortality at 6.2%.
In contrast, the operative mortality reported for
BAV or MFS patients was <3%.
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23712. The 15-year cumulative incidence of aortic dissec-
tion was higher in MFS (5.5%), and the incidence in
BAV patients (0.55%) was not different than the
control patients.
3. The 15-year cumulative incidence of thoracic an-
eurysms was much higher in the MFS (10.8%) and
BAV (4.8%) patients than in the control group
(1.4%).
4. The 15-year cumulative incidence of thoracic aortic
repair was again higher in the MFS (10.4%) or BAV
(2.5%) patients than in control patients (0.5%).
Indications for repair included aortic dissection in
30.8% of patients, with a mortality rate of 30.0%.
In contrast, the mortality rate for aortic aneurys-
mectomy on late follow-up was 10.8%.
The novel ﬁndings in this study describe the in-
termediate risk imposed by the presence of BAVs,
which appears to lie somewhere between MFS
patients and those from the general population.
These data importantly identiﬁed a relatively low risk
of aortic-related complications at late follow-up in
all groups of patients. The important caveat, howev-
er, is that the study group excluded a large number of
patients who underwent concomitant aortic repair.
Presumably, this excluded patients with smalleraneurysms that, if left alone, may have altered this
natural history to favor higher risks of aortic
complications.
Although this study is an important addition to the
current published data, several limitations exist.
Administrative databases have inherent data validity
limitations and are not as clinically robust, although
they do provide large sample sizes. Exclusion of a
large number of patients at the outset of the study,
as described previously, may have biased the con-
clusions against identifying aortic events in both
MFS and BAV patients.
All of these issues, when taken together with the
fundamental lack of knowledge regarding BAV syn-
drome, suggests that there is a need for a prospectively-
collected, clinically-robust database to further evaluate
the natural history and genetic underpinnings of this
complex, heterogeneous pathology.
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